News
ADXN
3.090
+5.46%
0.160
Addex Therapeutics Ltd Increases Issued Share Capital to Create Treasury Shares
NASDAQ · 1d ago
Weekly Report: what happened at ADXN last week (1019-1023)?
Weekly Report · 4d ago
Weekly Report: what happened at ADXN last week (1012-1016)?
Weekly Report · 10/19 10:21
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/15 21:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 10/15 12:12
Weekly Report: what happened at ADXN last week (1005-1009)?
Weekly Report · 10/12 10:27
Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial
NASDAQ · 10/08 11:42
Addex Therapeutics spin-out company completes NTX-253 clinical studies
TipRanks · 10/08 09:20
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
Barchart · 10/08 00:00
Weekly Report: what happened at ADXN last week (0928-1002)?
Weekly Report · 10/05 10:26
Addex's Rocher Returns As Head Of Pharmaceutical Development; Kalinichev Departs For Neurosterix
NASDAQ · 10/02 08:06
Addex Therapeutics Announces Executive Management Changes
Barchart · 10/02 00:00
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 09/28 21:06
Addex Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Benzinga · 09/28 14:57
CORRECTION: Addex Therapeutics Q2 EPADS $(2.16) Up From $(2.90) YoY, Sales $12.650K Down From $44.031K YoY
Benzinga · 09/28 14:10
Earnings Scheduled For September 28, 2026
Benzinga · 09/28 11:11
Weekly Report: what happened at ADXN last week (0921-0925)?
Weekly Report · 09/28 10:21
Addex Therapeutics H1 Net Loss Widens, Operating Loss Narrows; Advances GABAB PAM Cough Program
NASDAQ · 09/28 08:44
Addex Posts Narrower Loss In Q2
NASDAQ · 09/28 08:37
Addex Therapeutics reports 1H results
Seeking Alpha · 09/28 07:46
More
Webull provides a variety of real-time ADXN stock news. You can receive the latest news about Addex Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.